Disease Markers

Biomarkers and Therapeutic Targets of COVID-19 Pneumonia


Publishing date
01 Jul 2022
Status
Closed
Submission deadline
25 Feb 2022

1University of Eastern Piedmont, Novara, Italy

2Imperial College London, London, UK

3William Harvey Research Institute, London, UK

This issue is now closed for submissions.
More articles will be published in the near future.

Biomarkers and Therapeutic Targets of COVID-19 Pneumonia

This issue is now closed for submissions.
More articles will be published in the near future.

Description

Coronavirus disease (COVID-19) pneumonia is caused by an infection from the virus SARS-CoV-2. Its clinical manifestations encompass a wide range of entities, from a mild flu-like illness to life-threatening forms. While the flu-like clinical picture is the most common presentation, the evolution to respiratory failure due to COVID-19 pneumonia is the cause of in-hospital admission and may rapidly evolve to acute respiratory distress syndrome (ARDS).

Unfortunately, knowledge about the effects of SARS-CoV-2 on host targets remains largely limited, hampering our understanding of COVID-19 pathogenesis and the development of therapeutic strategies. To date, few biomarkers have been identified that, unfortunately, are individually poorly specific, therefore novel ones are needed to better predict patient outcome. Moreover, additional translational research efforts are needed to rapidly find new biological and molecular targets.

The aim of this Special Issue is to collect original research articles and review articles that highlight new biomarkers and therapeutic targets of pneumonia caused by COVID-19.

Potential topics include but are not limited to the following:

  • Current and novel biomarkers of COVID-19 clinical evolution
  • Current and novel biomarkers of inflammation related to COVID-19
  • Current and promising molecular and biological targets of COVID-19, particularly related to act on inflammation and lung injury
  • Current and novel biomarkers of organ damage related to morbidity or mortality due to COVID-19

Articles

  • Special Issue
  • - Volume 2022
  • - Article ID 6780710
  • - Research Article

Partial-Methylated HeyL Promoter Predicts the Severe Illness in Egyptian COVID-19 Patients

Hewida H. Fadel | Mohammad Abd EL-Rahman Ahmed | ... | Reda Almiry
  • Special Issue
  • - Volume 2022
  • - Article ID 4623901
  • - Research Article

Predicting Intensive Care Unit Admission for COVID-19 Patients from Laboratory Results

Basmah M. Azad Allarakia | Hattan S. Gattan | ... | Abdulrahman S. Bazaid
  • Special Issue
  • - Volume 2022
  • - Article ID 1568352
  • - Research Article

Baseline Plasma Gas6 Protein Elevation Predicts Adverse Outcomes in Hospitalized COVID-19 Patients

Stelvio Tonello | Manuela Rizzi | ... | Pier Paolo Sainaghi
  • Special Issue
  • - Volume 2022
  • - Article ID 3528312
  • - Research Article

Prognostic Markers in Hospitalized COVID-19 Patients: The Role of IP-10 and C-Reactive Protein

Manuela Rizzi | Martina Costanzo | ... | Pier Paolo Sainaghi
  • Special Issue
  • - Volume 2022
  • - Article ID 5106342
  • - Research Article

The Prognostic Role of Metabolic and Endocrine Parameters for the Clinical Severity of COVID-19

Shokoufeh Bonakdaran | Parvin Layegh | ... | Mohammad Ali Yaghoubi
  • Special Issue
  • - Volume 2021
  • - Article ID 7686374
  • - Research Article

Plasma S-Adenosylmethionine Is Associated with Lung Injury in COVID-19

Evgeny Vladimirovich Kryukov | Alexander Vladimirovich Ivanov | ... | Aslan Amirkhanovich Kubatiev
  • Special Issue
  • - Volume 2021
  • - Article ID 6304189
  • - Research Article

Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio

Yi Li | Haitao Li | ... | Minhui Dai
  • Special Issue
  • - Volume 2021
  • - Article ID 2571912
  • - Research Article

Value of the Neutrophil-Lymphocyte Ratio in Predicting COVID-19 Severity: A Meta-analysis

Ying Wang | Jingyi Zhao | ... | Yinhui Yao
  • Special Issue
  • - Volume 2021
  • - Article ID 4129993
  • - Research Article

Network Pharmacology Reveals That Resveratrol Can Alleviate COVID-19-Related Hyperinflammation

Zijian Xiao | Qing Ye | ... | Tao Xiang
Disease Markers
 Journal metrics
See full report
Acceptance rate23%
Submission to final decision60 days
Acceptance to publication23 days
CiteScore4.700
Journal Citation Indicator0.720
Impact Factor3.464
 Submit

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.